Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech? Health, page-5

Sam:
We need to add to our team someone like this.


CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:IONS) today announced that Damien McDevitt, Ph.D. has joined the company as chief business officer. In his role, Dr. McDevitt will serve as a member of Ionis' executive leadership team and will provide strategic guidance and lead Ionis' corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management.  



"Damien is a highly experienced and accomplished leader in the pharmaceutical industry. His strong background in both science and business enable him to contribute broadly in all areas of the company," said Brett P. Monia, chief operating officer and senior vice president, translational medicine. "His leadership will be invaluable as we continue to advance our large pipeline of Ionis-owned and partnered programs, maximize the commercial success of our drugs and optimize our participation in their commercial success. I am excited about the wealth of experience that Damien brings to Ionis, which will be instrumental as we become a multi-product, sustainably profitable company."

"I am joining Ionis at an exciting time. Just this year, Ionis has seen its first commercial drug for a neurological disease, SPINRAZA, reach blockbuster status. Ionis is continuing to build on this momentum with the planned launches of two new drugs this year and readouts from multiple important clinical studies in the near term from its robust pipeline of over 40 first-in-class or best-in-class drugs across multiple therapeutic areas," said Dr. McDevitt. "I look forward to applying my business and operational experience to complement and augment Ionis' goals to not only be the leader in antisense technology, but also a leader in the biotech industry, bringing important medicines to patients."